153 related articles for article (PubMed ID: 29292843)
1. Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).
Norris RE; Fox E; Reid JM; Ralya A; Liu XW; Minard C; Weigel BJ
Pediatr Blood Cancer; 2018 May; 65(5):e26944. PubMed ID: 29292843
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of ontuxizumab, a humanized monoclonal antibody targeting endosialin, in Japanese patients with solid tumors.
Doi T; Aramaki T; Yasui H; Muro K; Ikeda M; Okusaka T; Inaba Y; Nakai K; Ikezawa H; Nakajima R
Invest New Drugs; 2019 Oct; 37(5):1061-1074. PubMed ID: 30623276
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Geller JI; Perentesis JP; Liu X; Minard CG; Kudgus RA; Reid JM; Fox E; Blaney SM; Weigel BJ
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449393
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL; Fox E; Merchant MS; Reid JM; Kudgus RA; Liu X; Minard CG; Voss S; Berg SL; Weigel BJ; Mackall CL
Lancet Oncol; 2020 Apr; 21(4):541-550. PubMed ID: 32192573
[TBL] [Abstract][Full Text] [Related]
7. A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors.
Diaz LA; Coughlin CM; Weil SC; Fishel J; Gounder MM; Lawrence S; Azad N; O'Shannessy DJ; Grasso L; Wustner J; Ebel W; Carvajal RD
Clin Cancer Res; 2015 Mar; 21(6):1281-8. PubMed ID: 25398449
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas.
Jones RL; Chawla SP; Attia S; Schöffski P; Gelderblom H; Chmielowski B; Le Cesne A; Van Tine BA; Trent JC; Patel S; Wagner AJ; Chugh R; Heyburn JW; Weil SC; Wang W; Viele K; Maki RG
Cancer; 2019 Jul; 125(14):2445-2454. PubMed ID: 31034598
[TBL] [Abstract][Full Text] [Related]
9. A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.
D'Angelo SP; Hamid OA; Tarhini A; Schadendorf D; Chmielowski B; Collichio FA; Pavlick AC; Lewis KD; Weil SC; Heyburn J; Schweizer C; O'Shannessy DJ; Carvajal RD
Invest New Drugs; 2018 Feb; 36(1):103-113. PubMed ID: 29127533
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S
Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.
Burke MJ; Ahern C; Weigel BJ; Poirier JT; Rudin CM; Chen Y; Cripe TP; Bernhardt MB; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):743-50. PubMed ID: 25307519
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Pinto N; DuBois SG; Marachelian A; Diede SJ; Taraseviciute A; Glade Bender JL; Tsao-Wei D; Groshen SG; Reid JM; Haas-Kogan DA; Reynolds CP; Kang MH; Irwin MS; Macy ME; Villablanca JG; Matthay KK; Park JR
Pediatr Blood Cancer; 2018 Jul; 65(7):e27023. PubMed ID: 29603591
[TBL] [Abstract][Full Text] [Related]
17. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
Federico SM; Caldwell KJ; McCarville MB; Daryani VM; Stewart CF; Mao S; Wu J; Davidoff AM; Santana VM; Furman WL; Pappo AS; Navid F
Eur J Cancer; 2020 Jun; 132():35-42. PubMed ID: 32325418
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
19. Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.
Boal LH; Glod J; Spencer M; Kasai M; Derdak J; Dombi E; Ahlman M; Beury DW; Merchant MS; Persenaire C; Liewehr DJ; Steinberg SM; Widemann BC; Kaplan RN
Clin Cancer Res; 2020 Dec; 26(23):6112-6121. PubMed ID: 32943455
[TBL] [Abstract][Full Text] [Related]
20. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011).
Loh ML; Tasian SK; Rabin KR; Brown P; Magoon D; Reid JM; Chen X; Ahern CH; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2015 Oct; 62(10):1717-24. PubMed ID: 25976292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]